In recent years, high-priced drugs and devices have come under scrutiny as payers, clinicians, and policy makers seek to curb the growing cost of health care. Whereas drug and device companies have historically charged “what the market will bear,”1 innovative pricing models—collectively known as value-based pricing—are emerging in specialties, such as oncology,1 cardiology,1,2 and endocrinology,2 to better align the cost of these technologies with their capacity to improve health.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Rathi VK, Metson R, Scangas GA. The Case for Value-Based Pricing of Corticosteroid-Eluting Sinus Stents. JAMA Otolaryngol Head Neck Surg. 2020;146(3):221–222. doi:10.1001/jamaoto.2019.4407
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: